- Home
- DERM vs PALI Comparison
DERM vs PALI Comparison
Compare DERM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DERM | PALI |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.1M | 240.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DERM | PALI |
|---|---|---|
| Price | $8.25 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.67 | ★ $13.00 |
| AVG Volume (30 Days) | 82.7K | ★ 3.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,134,000.00 | $260,000.00 |
| Revenue This Year | $17.48 | N/A |
| Revenue Next Year | $55.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $4.97 | $0.55 |
| 52 Week High | $9.56 | $2.64 |
Technical Indicators
Market Signals| Indicator | DERM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 51.75 |
| Support Level | $6.71 | $1.65 |
| Resistance Level | $8.71 | $1.93 |
| Average True Range (ATR) | 0.48 | 0.12 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 57.68 | 62.16 |
Price Performance
Historical ComparisonAbout DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.